Jpmorgan Chase & CO Zai Lab LTD Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Zai Lab LTD stock. As of the latest transaction made, Jpmorgan Chase & CO holds 45,455 shares of ZLAB stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,455
Previous 161,635
71.88%
Holding current value
$1.56 Million
Previous $4.23 Million
61.21%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ZLAB
# of Institutions
170Shares Held
38.6MCall Options Held
150KPut Options Held
201K-
Capital World Investors Los Angeles, CA6.04MShares$207 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY5.54MShares$190 Million2.97% of portfolio
-
Clearbridge Investments, LLC New York, NY4.01MShares$138 Million0.12% of portfolio
-
Janus Henderson Group PLC London, X02.2MShares$75.4 Million0.04% of portfolio
-
Bamco Inc New York, NY1.59MShares$54.5 Million0.16% of portfolio
About Zai Lab Ltd
- Ticker ZLAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,908,704
- Market Cap $3.36B
- Description
- Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...